<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659799</url>
  </required_header>
  <id_info>
    <org_study_id>FiAsp-Exercise</org_study_id>
    <nct_id>NCT03659799</nct_id>
  </id_info>
  <brief_title>Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes</brief_title>
  <official_title>A Double-blind, Randomized, Cross-over Study to Compare the Impact of Rapid-acting Insulin Aspart and Faster Acting Aspart (FiAsp) on Glucose Excursion During Postprandial Exercise in Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Recherches Cliniques de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoglycemia is the main barrier for physical activity practice of patients with type 1&#xD;
      diabetes (T1D). For postprandial exercise, anticipation with meal insulin bolus reduction is&#xD;
      the recommended method to reduce exercise-associated hypoglycemic risk. The impact of faster&#xD;
      acting Aspart (FiAsp) pharmacokinetic on hypoglycemic risk has not yet been explored. This&#xD;
      study will explore two different timings for exercise onset.&#xD;
&#xD;
      Objective: To compare the impact of rapid-acting insulin Aspart and faster acting Aspart&#xD;
      (FiAsp) on glucose reduction during exercise.&#xD;
&#xD;
      Design: This study is a randomized, four-way, crossover study to compare the efficacy of 1)&#xD;
      rapid-acting insulin Aspart, and 2) FiAsp on glucose reduction during an exercise performed&#xD;
      60 minutes or 120 minutes after breakfast. The insulin used and the timing of the exercise&#xD;
      will be randomized. This project will be conducted at Institut de recherches cliniques de&#xD;
      Montr√©al (IRCM, Montreal, Canada).&#xD;
&#xD;
      Hypothesis: Faster acting Aspart (FiAsp) will be non-inferior to insulin Aspart for&#xD;
      hypoglycemic risk.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in plasma glucose levels during exercise</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
    <description>Difference between glucose levels at the beginning of the exercise and the lowest glucose levels from the start of the exercise until the end of the exercise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent below 4 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decremental area under the curve of plasma glucose levels</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of plasma glucose levels below 4 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with an exercise-induced hypoglycemia below 3.9 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with an exercise-induced hypoglycemia below 3.3 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring an oral treatment for hypoglycemia</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of hypoglycemia episodes requiring treatment</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent above 10 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent between 4 and 10 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time (minutes) to the first hypoglycemic event</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of carbohydrates needed to treat a hypoglycemic event</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxyhemoglobin in the vastus lateralis</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in deoxyhemoglobin in the vastus lateralis</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total hemoglobin in the vastus lateralis</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent between 4 and 10 mmol/L</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent below 4 mmol/L</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent above 10 mmol/L</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of plasma glucose levels below 4 mmol/L</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring an oral treatment for hypoglycemia</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of hypoglycemia episodes requiring treatment</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of carbohydrates needed to treat hypoglycemic events</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of plasma glucose levels</measure>
    <time_frame>4.5 hours (entire protocol period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of hypoglycemia episodes requiring treatment</measure>
    <time_frame>4.5 hours (entire protocol period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of carbohydrates needed to treat hypoglycemic events</measure>
    <time_frame>4.5 hours (entire protocol period)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Aspart - 60-minutes postprandial exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspart - 120-minutes postprandial exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FiAsp - 60-minutes postprandial exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FiAsp - 120-minutes postprandial exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin FiAsp</intervention_name>
    <description>An insulin bolus of FiAsp will be given 5 minutes before breakfast</description>
    <arm_group_label>FiAsp - 120-minutes postprandial exercise</arm_group_label>
    <arm_group_label>FiAsp - 60-minutes postprandial exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>An insulin bolus of Aspart will be given 5 minutes before breakfast</description>
    <arm_group_label>Aspart - 120-minutes postprandial exercise</arm_group_label>
    <arm_group_label>Aspart - 60-minutes postprandial exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>60-minutes postprandial exercise</intervention_name>
    <description>A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast</description>
    <arm_group_label>Aspart - 60-minutes postprandial exercise</arm_group_label>
    <arm_group_label>FiAsp - 60-minutes postprandial exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>120-minutes postprandial exercise</intervention_name>
    <description>A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast</description>
    <arm_group_label>Aspart - 120-minutes postprandial exercise</arm_group_label>
    <arm_group_label>FiAsp - 120-minutes postprandial exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females ‚â• 18 years of old.&#xD;
&#xD;
          2. Clinical diagnosis of type 1 diabetes for at least one year.&#xD;
&#xD;
          3. HbA1c ‚â§ 9.5%.&#xD;
&#xD;
          4. Patients using multiple daily injections with basal-bolus insulin regimen and insulin&#xD;
             analogs (pre-meal: Aspart, Lispro, Guilisine or Fiasp; basal: Detemir, Glargine U100 &amp;&#xD;
             U300, Degludec U100).&#xD;
&#xD;
          5. Written informed consent given.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant microvascular complications: nephropathy (estimated glomerular&#xD;
             filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or&#xD;
             severe proliferative retinopathy as judged by the investigator.&#xD;
&#xD;
          2. Recent (&lt; 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac&#xD;
             surgery.&#xD;
&#xD;
          3. Anemia (Hb &lt; 100g/L).&#xD;
&#xD;
          4. Ongoing pregnancy or breastfeeding.&#xD;
&#xD;
          5. Severe hypoglycemic episode within two weeks of screening.&#xD;
&#xD;
          6. Other serious medical illness likely to interfere with study participation or with the&#xD;
             ability to complete the exercise periods by the judgment of the investigator (e.g.&#xD;
             orthopedic limitation).&#xD;
&#xD;
          7. Ongoing treatment with CSII (Continuous Subcutaneous Insulin Infusion) &quot;insulin pump&#xD;
             therapy&quot;.&#xD;
&#xD;
          8. Participation to a clinical trial in the last 3 months prior to inclusion in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remi Rabasa-Lhoret</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de recherches cliniques de Montr√©al</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne Supp√®re</last_name>
    <phone>514-987-5597</phone>
    <email>corinne.suppere@ircm.qc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de recherches cliniques de Montr√©al</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Supp√®re</last_name>
      <email>corinne.suppere@ircm.qc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

